- Home
- PDX vs COLL Comparison
PDX vs COLL Comparison
Compare PDX & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDX
- COLL
- Stock Information
- Founded
- PDX 2019
- COLL 2002
- Country
- PDX NY
- COLL United States
- Employees
- PDX N/A
- COLL N/A
- Industry
- PDX Finance/Investors Services
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- PDX Finance
- COLL Health Care
- Exchange
- PDX Nasdaq
- COLL Nasdaq
- Market Cap
- PDX 1.1B
- COLL 947.6M
- IPO Year
- PDX N/A
- COLL 2015
- Fundamental
- Price
- PDX $24.83
- COLL $29.83
- Analyst Decision
- PDX
- COLL Strong Buy
- Analyst Count
- PDX 0
- COLL 4
- Target Price
- PDX N/A
- COLL $43.75
- AVG Volume (30 Days)
- PDX N/A
- COLL 269.0K
- Earning Date
- PDX 01-01-0001
- COLL 08-07-2025
- Dividend Yield
- PDX 4.95%
- COLL N/A
- EPS Growth
- PDX N/A
- COLL N/A
- EPS
- PDX N/A
- COLL 1.25
- Revenue
- PDX N/A
- COLL $664,283,000.00
- Revenue This Year
- PDX N/A
- COLL $20.04
- Revenue Next Year
- PDX N/A
- COLL $3.98
- P/E Ratio
- PDX N/A
- COLL $23.39
- Revenue Growth
- PDX N/A
- COLL 17.17
- 52 Week Low
- PDX $13.52
- COLL $23.23
- 52 Week High
- PDX $21.05
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- PDX 72.57
- COLL 55.48
- Support Level
- PDX $24.63
- COLL $29.11
- Resistance Level
- PDX $25.25
- COLL $30.22
- Average True Range (ATR)
- PDX 0.43
- COLL 0.70
- MACD
- PDX 0.05
- COLL -0.06
- Stochastic Oscillator
- PDX 82.50
- COLL 49.89
About PDX PIMCO Dynamic Income Strategy Fund of Beneficial Interest
PIMCO Dynamic Income Strategy Fund is a non-diversified, limited term, closed-end management investment company registered under the Investment Company. The fund's primary investment objective is to seek current income as a primary objective and capital appreciation as a secondary objective.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.